- cIAP2 (cellular Inhibitor of Apoptosis Protein 2) is a multifunctional signalling protein belonging to the IAP family, where it works closely with cIAP1 and XIAP to regulate apoptosis, ubiquitination and innate immune signalling. Although structurally similar to cIAP1, cIAP2 has distinct regulatory roles in inflammation, NF‑κB signalling and cell fate decisions. Its ability to assemble K63‑linked ubiquitin chains makes cIAP2 a central checkpoint in TNF receptor signalling and NOD2‑mediated immune responses.
- cIAP2 contains three BIR (Baculovirus IAP Repeat) domains and a C‑terminal RING finger domain. The BIR domains mediate interactions with TRAF proteins and other signalling adaptors, while the RING domain functions as an E3 ubiquitin ligase. Through this ligase activity, cIAP2 ubiquitinates RIPK1 and RIPK2, stabilising pro‑survival signalling complexes and promoting canonical and non‑canonical NF‑κB activation. As long as cIAP2 is present and active, TNF stimulation leads to inflammation and cell survival rather than apoptosis.
- One of the defining features of cIAP2 is its role in the non‑canonical NF‑κB pathway. cIAP2 forms a complex with TRAF2 and TRAF3 to regulate NIK (NF‑κB‑inducing kinase). By ubiquitinating NIK, cIAP2 prevents its accumulation and suppresses non‑canonical NF‑κB activation. When cIAP2 is depleted—either through Smac mimetics or cellular stress—NIK stabilises, leading to p100 processing and activation of RelB‑dependent transcription. This pathway is crucial in chronic inflammation, lymphoid organ development and certain cancers.
- cIAP2 also participates in innate immune signalling through the NOD2 pathway. By ubiquitinating RIPK2, cIAP2 promotes NF‑κB activation in response to bacterial peptidoglycan. Mutations in BIRC3, the gene encoding cIAP2, are associated with immune dysregulation and lymphoid malignancies, highlighting its importance in host defence and inflammation.
- Like cIAP1, cIAP2 is regulated by mitochondrial proteins released during apoptosis. Smac/DIABLO binds cIAP2 and promotes its autoubiquitination and degradation. Smac mimetics—small molecules that mimic Smac/DIABLO—trigger rapid depletion of cIAP1 and cIAP2, sensitising cells to TNF‑induced apoptosis. This mechanism is being explored in cancer therapy, where cIAP2 overexpression contributes to tumour survival and resistance to treatment.
- In cancer biology, cIAP2 is frequently upregulated in lymphomas, multiple myeloma and solid tumours. Its role in maintaining NF‑κB signalling and suppressing apoptosis makes it a key therapeutic target. Inhibiting cIAP2 destabilises tumour survival pathways and restores sensitivity to cell death signals.
- In summary, cIAP2 is a critical regulator of apoptosis, ubiquitination and inflammatory signalling. By controlling RIPK1 and RIPK2 ubiquitination, cIAP2 determines whether TNF and NOD2 signalling promote cell survival or trigger apoptosis. Its roles in immunity, inflammation and cancer make cIAP2 a major focus in molecular biology and therapeutic development.
